18261051. MEASLES-HIV OR MEASLES-HTLV VACCINE simplified abstract (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)

MEASLES-HIV OR MEASLES-HTLV VACCINE

Organization Name

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor(s)

Thierry Heidmann of VILLEJUIF CEDEX (FR)

Frederic Tangy of PARIS CEDEX 15 (FR)

MEASLES-HIV OR MEASLES-HTLV VACCINE - A simplified explanation of the abstract

This abstract first appeared for US patent application 18261051 titled 'MEASLES-HIV OR MEASLES-HTLV VACCINE

Simplified Explanation

The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus-like particles (VLPs) containing proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after administration. The invention provides nucleic acid constructs, vectors, cells, and rescue systems to produce these recombinant infectious particles. It also relates to the use of these particles, particularly in vaccine formulations, for the treatment or prevention of HIV or HTLV infections.

• Recombinant measles virus expressing IV or HTLV polypeptides
• Immunogenic immunodeficiency virus particles expressed by measles virus
• Virus-like particles containing proteins of immunodeficiency virus or HTLV
• Recombinant infectious particles capable of replication in a host
• Nucleic acid constructs, vectors, cells, and rescue systems for production
• Use in vaccine formulations for HIV or HTLV infection treatment or prevention

Potential Applications

The technology could be used in the development of vaccines for HIV or HTLV infections.

Problems Solved

This technology addresses the need for effective vaccines against HIV and HTLV infections.

Benefits

The technology offers a potential solution for preventing or treating HIV and HTLV infections through vaccine development.

Potential Commercial Applications

The technology has potential applications in the pharmaceutical industry for the production of vaccines against HIV and HTLV infections.

Possible Prior Art

Prior art may include research on recombinant viral vectors for vaccine development against various viral infections.

Unanswered Questions

What are the specific mechanisms by which the recombinant measles virus expressing IV or HTLV polypeptides elicits an immune response against HIV or HTLV infections?

The specific mechanisms of action of the recombinant measles virus in generating an immune response against HIV or HTLV infections are not detailed in the abstract.

How do the immunogenic immunodeficiency virus particles expressed by the measles virus contribute to the efficacy of the vaccine in preventing or treating HIV or HTLV infections?

The abstract does not provide information on how the immunogenic immunodeficiency virus particles enhance the effectiveness of the vaccine against HIV or HTLV infections.

Original Abstract Submitted

The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.